Estrogen modulation of osteoclast lysosomal enzyme secretion

Area of Science:

• Endocrinology
• Cell Biology
• Bone Biology

Background:

• Osteoclast-mediated bone resorption is crucial for skeletal remodeling.
• Lysosomal proteases secreted by osteoclasts contribute to bone breakdown.
• Estrogen, specifically 17 beta-estradiol (17 beta-E2), has been shown to inhibit bone resorption.

Purpose of the Study:

• To investigate the mechanism by which 17 beta-E2 affects lysosomal enzyme production and secretion in osteoclasts.
• To determine the impact of 17 beta-E2 on specific lysosomal enzymes involved in bone resorption.

Main Methods:

• Isolated avian osteoclasts and human giant cell tumor cells were cultured with bone particles.
• Cells were treated with varying doses of 17 beta-E2 or vehicle.
• Secreted and cell-associated levels of cathepsin B, cathepsin L, beta-glucuronidase, lysozyme, and tartrate-resistant acid phosphatase (TRAP) were quantified.

Main Results:

• 17 beta-E2 treatment caused a dose-dependent decrease in secreted lysosomal enzymes.
• Cell-associated levels of cathepsin L, beta-glucuronidase, and lysozyme decreased, while cathepsin B and TRAP increased.
• These effects were observed at nanomolar concentrations of 17 beta-E2 and were steroid-specific, being blocked by an estrogen antagonist.

Conclusions:

• 17 beta-E2 significantly alters lysosomal enzyme activity in osteoclasts, contributing to reduced bone resorption.
• The findings elucidate a key molecular mechanism for estrogen's effect on bone metabolism.
• This research provides a basis for understanding estrogen's role in bone diseases and potential therapeutic targets.